Search ANIP
ANI PHARMACEUTICALS INC
Nasdaq · CIK 1023024
Last close72.18
Daily change-0.78 (-1.07%)
10 Years gain+7.59%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ANIP · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
83.5Momentum
93.6Acceleration
96.2Confidence
83.0Annual Revenue17
Quarterly Revenue68
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality23.2 / 25
Capital Efficiency17.6 / 20
Balance Sheet13.5 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.3071 percentage points.
Operating leverageOperating margin improved by 8.7175 percentage points.
ROIC expansionROIC improved by 13.2741 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Heavy share dilution · HIGHDiluted share count increased 9.3236%.
Key Metrics
Revenue Growth TTM51.82%OK
Revenue CAGR 3Y40.81%OK
Gross Margin53.83%OK
Operating Margin13.74%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC16.93%OK
Incremental Operating Margin 3Y25.68%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y9.32%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $883.37M | $480.50M | $111.09M | $185.23M | $171.39M | 54.39% | 12.58% | 19.4% | 15.92% | 21.23M |
| 2025 FY Dec 31, 2024 | $614.38M | $294.80M | $584,000.00 | $64.02M | $47.78M | 47.98% | 0.1% | 7.78% | 0.09% | 19.32M |
| 2025 FY Dec 31, 2023 | $486.82M | $242.95M | $46.97M | $118.96M | $110.09M | 49.91% | 9.65% | 22.61% | 8.46% | 18.19M |
| 2024 FY Dec 31, 2022 | $316.39M | $111.08M | -$35.28M | -$31.20M | -$40.08M | 35.11% | -11.15% | -12.67% | -5.2% | 16.26M |
| 2023 FY Dec 31, 2021 | $216.14M | $55.87M | -$39.79M | $3.32M | $765,000.00 | 25.85% | -18.41% | 0.35% | -7.03% | 12.6M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $942.69M | sum latest 4 fiscal quarters Revenue | OK | 0001023024-26-000069, 0001023024-25-000108 |
| Revenue Growth TTM | 51.82% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001023024-26-000069, 0001023024-25-000108 |
| Revenue CAGR 3Y | 40.81% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001023024-26-000014 |
| Revenue CAGR 5Y | 33.48% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001023024-26-000014 |
| Gross Profit CAGR 3Y | 62.94% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001023024-26-000014 |
| Operating Income Growth | 315.59% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001023024-26-000069, 0001023024-25-000108 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 53.83% | Gross Profit / Revenue | OK | 0001023024-26-000069, 0001023024-25-000108 |
| Operating Margin | 13.74% | Operating Income / Revenue | OK | 0001023024-26-000069, 0001023024-25-000108 |
| ROIC | 16.93% | NOPAT / Average Invested Capital | OK | 0001023024-26-000069, 0001023024-25-000108 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001023024-26-000069 |
| Current Ratio | 2.91x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.19x | (Cash + Short-term Investments) / Total Debt | OK | 0001023024-26-000069 |
| Revenue per Diluted Share | $43.02 | Revenue / Diluted Shares | OK | 0001023024-26-000069, 0001023024-25-000108 |